Aqueous Humor Biomarkers, Efficacy, and Safety in Patients with Naïve Diabetic Macular Edema Treated with Faricimab: The ALTIMETER Study
Ophthalmology Science · 2026-05 · 6 (5) · 101129
DOI: 10.1016/j.xops.2026.101129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmology Science, 2026-05. Verfasst von Patricio G Schlottmann und 16 weiteren Autor:innen. Beteiligte Einrichtung: Charles Centro Oftalmologico, Buenos Aires, Argentina. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F. Hoffmann-La Roche Ltd.
Abstract (Originalsprache)
Objective
To explore associations between clinical endpoints, multimodal imaging, and aqueous humor (AH) biomarker patterns in patients with diabetic macular edema (DME) treated with faricimab.
Design
A phase IIb, multicenter, open-label, single-arm, 24-week exploratory study.
Participants
Adults with treatment-naïve DME, best-corrected visual acuity (BCVA) of 20-75 ETDRS letters, and central subfield thickness (CST) ≥325 μm were eligible to participate.
Methods
Patients received six 4-weekly intravitreal doses of faricimab 6.0 mg. Functional and multimodal imaging assessments were conducted through week 24. Aqueous humor samples were collected at baseline and week 16 for targeted proteomic analysis. Patients were monitored for safety. Main Outcome Measures: Prespecified exploratory endpoints included changes from baseline over time in BCVA, CST, the proportion of patients with ≥2-step ETDRS Diabetic Retinopathy Severity Scale (DRSS) improvement, intraretinal/subretinal fluid and macular leakage on multimodal imaging, and AH biomarker patterns.
Results
Ninety-nine patients were enrolled. At week 24, treatment with faricimab resulted in clinical and anatomical improvements consistent with phase III trials in DME (YOSEMITE/RHINE); the adjusted mean (95% confidence interval) change from baseline was +9.2 (7.5-10.9) letters for BCVA and -200.2 μm (-214.1 to -186.2) for CST, and 50.0% (37.2-62.8) of patients achieved ≥2-step DRSS improvement. Macular leakage area reduced from a median (interquartile range) of 28.6 mm2 (16.9-36.5) at baseline to 2.8 mm2 (0.9-15.3) at week 20. Total AH protein concentration decreased significantly from baseline to week 16 (P < 0.0001), with reductions across plasma-derived, inflammatory, and hypoxia response proteins. Notably, faricimab treatment significantly reduced the levels of key proteins associated with worse baseline DRSS scores (including angiopoietin-2, placental growth factor, and erythropoietin) and high baseline macular leakage, suggesting normalization of the AH proteomic profile. Safety was consistent with the known safety profile of faricimab.
Conclusions
In patients with treatment-naïve DME, faricimab treatment resulted in meaningful improvements in functional and anatomical outcomes. These clinical gains were accompanied by a significant reduction in the levels of key AH proteins associated with disease severity, which underscores their potential as biomarkers for assessing disease activity and therapeutic response. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Charles Centro Oftalmologico, Buenos Aires, Argentina.
- Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
- Genentech, Inc, South San Francisco, California.
- F. Hoffmann-La Roche Ltd, Basel, Switzerland.
- Roche Products Ltd, Welwyn Garden City, United Kingdom.
- Retina Consultants of Austin and Austin Research Center for Retina, Austin, Texas.
Förderung
- F. Hoffmann-La Roche Ltd
Zitieren
APA
Schlottmann, P. G., Fawzi, A. A., Amador, M., Dieckmann, A., Gibson, K., Glittenberg, C., Jhaveri, C., Kotak, A., Mar, F., Neubert, A., Sheth, V. S., Souverain, A., Titz, B., Vazquez-Lombardi, C., Wykoff, C. C., Ziemssen, F., & Vujosevic, S. (2026). Aqueous Humor Biomarkers, Efficacy, and Safety in Patients with Naïve Diabetic Macular Edema Treated with Faricimab: The ALTIMETER Study. Ophthalmology Science, 6(5), 101129. https://doi.org/10.1016/j.xops.2026.101129
Vancouver
Schlottmann PG, Fawzi AA, Amador M, Dieckmann A, Gibson K, Glittenberg C, et al. Aqueous Humor Biomarkers, Efficacy, and Safety in Patients with Naïve Diabetic Macular Edema Treated with Faricimab: The ALTIMETER Study. Ophthalmology Science. 2026;6(5):101129. doi:10.1016/j.xops.2026.101129
BibTeX
@article{Schlottmann2026,
author = {Schlottmann, Patricio G and Fawzi, Amani A and Amador, Manuel and Dieckmann, Andreas and Gibson, Kara and Glittenberg, Carl and Jhaveri, Chirag and Kotak, Alex and Mar, Florie and Neubert, Ales and Sheth, Veeral S and Souverain, Audrey and Titz, Bjoern and Vazquez-Lombardi, Claudia and Wykoff, Charles C and Ziemssen, Focke and Vujosevic, Stela},
title = {Aqueous Humor Biomarkers, Efficacy, and Safety in Patients with Naïve Diabetic Macular Edema Treated with Faricimab: The ALTIMETER Study},
journal = {Ophthalmology Science},
year = {2026},
volume = {6},
number = {5},
pages = {101129},
doi = {10.1016/j.xops.2026.101129}
}
EUVIMED